Chen Xiaofeng, Hu Xudong, Lin Huanmei, Li Ziang, Gao Baijun, Ouyang Hongmei, Hu Xiangdan, Xiao Jing
The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
Department of Gynecology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
Front Oncol. 2025 May 8;15:1577110. doi: 10.3389/fonc.2025.1577110. eCollection 2025.
The treatment of epithelial ovarian cancer (EOC) is evolving towards personalization and precision. Early prediction of recurrence can provide a basis for individualized monitoring and treatment. Our study aims to develop a predictive model for early recurrence of ovarian cancer incorporating Traditional Chinese Medicine (TCM) treatment.
We reviewed the clinicopathological and prognostic data of EOC patients who achieved complete clinical remission after surgery and chemotherapy at Guangdong Traditional Chinese Medicine Hospital (GPHCM) between December 2011 and July 2022. Basic information, clinical characteristics, treatment plans, and follow-up data were collected. Univariate logistic analysis was performed to identify significant variables (<0.10), followed by Least Absolute Shrinkage and Selection Operator (LASSO) regression to further determine key risk factors. A multivariate logistic regression model was constructed based on these factors, and a nomogram was developed to predict recurrence risk. The model's effectiveness was internally validated using bootstrap resampling (1000 iterations) and assessed for discrimination and calibration using Area Under Curve (AUC), the Hosmer-Lemeshow test, and calibration plots. Additionally, decision curve analysis (DCA) was performed to evaluate the clinical utility of the model.
This study included a total of 170 patients. Multivariate logistic regression analysis revealed that surgical procedure, The International Federation of Gynecology and Obstetrics (FIGO) stage, completion of the full chemotherapy course, and exposure to TCM were independent prognostic factors for ovarian cancer recurrence. Based on these factors, this study developed a nomogram model to predict recurrence risk, incorporating four key variables. The AUC of the prediction model was 0.843 (95% CI: 0.774-0.898), and the Hosmer-Lemeshow test and calibration plot indicated good calibration. DCA showed the model provided higher net benefit across a wide range of threshold probabilities.
The nomogram we developed effectively predicted 2-year recurrence risk in epithelial ovarian cancer patients. Notably, TCM treatment lasting more than 6 months may help prolong progression-free survival (PFS).
上皮性卵巢癌(EOC)的治疗正朝着个性化和精准化发展。复发的早期预测可为个体化监测和治疗提供依据。我们的研究旨在建立一个纳入中医(TCM)治疗的卵巢癌早期复发预测模型。
我们回顾了2011年12月至2022年7月在广东省中医院(GPHCM)接受手术和化疗后达到临床完全缓解的EOC患者的临床病理和预后数据。收集基本信息、临床特征、治疗方案和随访数据。进行单因素逻辑分析以确定显著变量(<0.10),随后进行最小绝对收缩和选择算子(LASSO)回归以进一步确定关键危险因素。基于这些因素构建多因素逻辑回归模型,并开发列线图以预测复发风险。使用自抽样法(1000次迭代)对模型的有效性进行内部验证,并使用曲线下面积(AUC)、Hosmer-Lemeshow检验和校准图评估其区分度和校准度。此外,进行决策曲线分析(DCA)以评估模型的临床实用性。
本研究共纳入170例患者。多因素逻辑回归分析显示,手术方式、国际妇产科联盟(FIGO)分期、完成全程化疗以及接受中医治疗是卵巢癌复发的独立预后因素。基于这些因素,本研究开发了一个列线图模型来预测复发风险,纳入了四个关键变量。预测模型的AUC为0.843(95%CI:0.774-0.898),Hosmer-Lemeshow检验和校准图显示校准良好。DCA表明该模型在广泛的阈值概率范围内提供了更高的净效益。
我们开发的列线图有效地预测了上皮性卵巢癌患者的2年复发风险。值得注意的是,持续超过6个月的中医治疗可能有助于延长无进展生存期(PFS)。